U.S. Stem Cell Inc. Announces Launch of US Stem Cell Middle East

Sunrise, FL – November 16, 2016 – U.S. STEM CELL, INC., a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients, is pleased to announce an agreement with Kuwait-based High Rising Group to launch U. S. Stem Cell Middle East.

U.S. Stem Cell, Inc. has recently signed a new licensing agreement with High Rising Group to open and operate regenerative medicine clinics throughout the Middle East. Patients suffering from chronic conditions including neurological, autoimmune, cardiovascular, COPD, and orthopedic ailments will now have access to stem cell therapy and other alternative medical treatments at any of our partner’s clinics in Dubai, Kuwait, Qatar, Bahrain, UAE, Saudi Arabia, Jordan and Egypt.

U.S. Stem Cell Middle East will offer regenerative treatment options to patients, based on U.S. Stem Cell, Inc. products and technologies like MyoCell, AdipoCell, and our Platelet Rich Plasma (PRP) method. U.S. Stem Cell, Inc. is hopeful that our stem cell therapies will transform the lives of patients worldwide.

“We at U.S. Stem Cell corporate are very happy and excited to partner with Ali Al Obaid and High Rising Group Company, said Mike Tomás, President and CEO of US Stem Cell Inc. “This partnership and licensing agreement will allow us to reach patients all over the world with our groundbreaking regenerative therapies. We believe that our innovative stem cell solutions can hopefully change the lives of those suffering from degenerative diseases in the Middle East.”

Managing Director of High Rising Group, Ali Al Obaid further stated “We are proud to bring first world regenerative medicine technologies to the Middle East via Kuwait and Dubai. After extensive research, we believe that US Stem Cell is the right partner to help our patients in the Middle East.”


About U.S. Stem Cell, Inc.

US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business, which includes three operating divisions (US Stem Cell Training, Vetbiologics and US Stem Cell Clinic) includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2015, and its Quarterly Reports on Form 10-Q.